Last reviewed · How we verify
Vimpat (lacosamide)
At a glance
| Generic name | lacosamide |
|---|---|
| Sponsor | UCB |
| Target | Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Idiopathic generalized epilepsy
- Partial Epilepsy Treatment Adjunct
- Tonic-clonic seizure in patients with epilepsy
Common side effects
- Diplopia
- Headache
- Dizziness
- Nausea
- Somnolence
- Injection site pain or discomfort
- Paresthesia
- Constipation
- Dyspepsia
- Dry mouth
- Cognitive disorder
- Hypoaesthesia
Serious adverse events
- Suicidal Behavior and Ideation
- Ataxia
- Cardiac Rhythm and Conduction Abnormalities
- Syncope
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions
- Elevated ALT (≥3x ULN)
- Hepatitis with transaminases >20x ULN
- Nephritis
- Profound Bradycardia
- Cerebellar syndrome
Key clinical trials
- Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing: an Exploratory Study in Healthy Volunteers (The Polo Study) (Phase 4)
- Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (Phase 2)
- Efficacy of Lacosamide in Neonatal Status Epilepticus: A Randomized Controlled Study (Phase 3)
- A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide in Children (>= 1 Month to < 17 Years of Age) With Epilepsy (Phase 2)
- A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partia (Phase 3)
- Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With (Phase 3)
- Lacosamide IV and EEG/EKG (LIVE) Study (Phase 2)
- Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) (Phase 3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11337943 | 2040-06-05 | Formulation |
| 12042474 | 2040-06-05 | Formulation |
| 11883374 | 2040-06-05 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vimpat CI brief — competitive landscape report
- Vimpat updates RSS · CI watch RSS
- UCB portfolio CI